Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.12 per share a year ago, resulting in an earnings surprise of +18.85% [1] Financial Performance - The company achieved revenues of $814.32 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.19%, but an increase from $730.52 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Performance - Amneal shares have increased approximately 15% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $753.87 million, and for the current fiscal year, it is $0.96 on revenues of $3.21 billion [7] - The estimate revisions trend for Amneal was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [8]

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.01%. A quarter ago, it was expected that this company would post a loss of $1.27 per share when it actually produced a loss of $1.38, delivering a surprise of -8.66%.Over the last four quarters, the co ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.99%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.88 per share when it actually produced earnings of $2.25, delivering a surprise of +19.68%.Over t ...

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.59%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.12, delivering a surprise of +7.69%.Over the last four qua ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.79%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.16 per share when it actually produced earnings of $0.23, delivering a surprise of +43.75%.Over the last fou ...

Core Insights - Ionis Pharmaceuticals reported an EPS of -$1.41, missing consensus estimates of around -$1.23, but exceeded revenue expectations with $203 million in total revenue [1][3] - The company has shown a pattern of revenue beats in recent quarters despite a year-over-year decline in Q4 total revenue [4] Financial Performance - Ionis reported a total revenue of $203 million for Q4 2025, which is an ~11% decline from $227 million in Q4 2024, but surpassed the Zacks Consensus Estimate by ~30% [3][4] - Commercial revenue grew approximately 64% to ~$141 million in Q4, driven by products like TRYNGOLZA, offsetting declines in royalties and R&D revenue [4] - The current ratio stands at approximately 2.79, indicating good short-term financial health despite ongoing unprofitability [2][5] Valuation Metrics - Ionis has a negative price-to-earnings (P/E) ratio of approximately -50, indicating current unprofitability [5] - The price-to-sales ratio is about 13, suggesting investors are willing to pay a premium for revenue amid pipeline expectations [5] - The enterprise value to sales ratio is also approximately 13, reflecting the company's valuation relative to revenue [5] Future Outlook - Ionis is focused on discovering and developing RNA-targeted therapeutics, with multiple independent launches planned for 2026 [2] - CEO Brett P. Monia emphasized the potential for continued success in 2026, highlighting upcoming launches such as olezarsen for sHTG and zilganersen for AxD [4]

United Therapeutics (UTHR) came out with quarterly earnings of $7.7 per share, beating the Zacks Consensus Estimate of $6.78 per share. This compares to earnings of $6.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +13.50%. A quarter ago, it was expected that this drugmaker would post earnings of $6.89 per share when it actually produced earnings of $7.16, delivering a surprise of +3.92%.Over the last four quarters, the co ...

The market expects Esperion Therapeutics (ESPR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other ha ...

Rigel Pharmaceuticals (RIGL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, t ...